6 doctors weighed in:

What's new in treatment for relapsing remitting ms

6 doctors weighed in
2 doctors agree

In brief: Stay tuned

Stay tuned! this field is changing rapidly.
Whereas injectable medications are the first tier of therapy, we are entering an era of oral medications and infrequent infusion therapies. Choosing the right therapy from this more and more crowded field of contenders will only get more complex. An MS specialist can help guide the discussion so that individuals can make the best informed choice.

In brief: Stay tuned

Stay tuned! this field is changing rapidly.
Whereas injectable medications are the first tier of therapy, we are entering an era of oral medications and infrequent infusion therapies. Choosing the right therapy from this more and more crowded field of contenders will only get more complex. An MS specialist can help guide the discussion so that individuals can make the best informed choice.
Dr. Virginia Simnad
Dr. Virginia Simnad
Thank
Dr. Olav Jaren
Neurology
1 doctor agrees

In brief: Many are coming out

There are many new treatments coming out soon.
What is new depends on what you know. Longer-acting injections and oral medicines are fairly new. Here is a link to more information: http://www.neurocuro.com/medicines-used-to-treat-ms/

In brief: Many are coming out

There are many new treatments coming out soon.
What is new depends on what you know. Longer-acting injections and oral medicines are fairly new. Here is a link to more information: http://www.neurocuro.com/medicines-used-to-treat-ms/
Dr. Olav Jaren
Dr. Olav Jaren
Thank

In brief: A few items

Research in progressive MS is ongoing, and best potential for Gilenya or Tysabri, (natalizumab) but not yet clear. Aubagio might have promise to control earliest onset (CIS).
Newest drug for R/R is Tecfidera, and Lemtrada is likely to emerge on market late this year. Research on ocrelizamab, laquinamod, daclizamab, and a new Plegridy injection also new. The latest Copaxone at thrice weekly injection is here

In brief: A few items

Research in progressive MS is ongoing, and best potential for Gilenya or Tysabri, (natalizumab) but not yet clear. Aubagio might have promise to control earliest onset (CIS).
Newest drug for R/R is Tecfidera, and Lemtrada is likely to emerge on market late this year. Research on ocrelizamab, laquinamod, daclizamab, and a new Plegridy injection also new. The latest Copaxone at thrice weekly injection is here
Dr. Bennett Machanic
Dr. Bennett Machanic
Thank
Dr. William Gaya
Neurology

In brief: Multiple sclerosis

The latest treatment for relapsing remitting multiple sclerosis is the long awaited tecfidera (dimethyl fumerate) also known as bg12.
This is an oral therapy twice a day with one week titration and little monitoring involved. Offers near 50% reduction in relapse rate.

In brief: Multiple sclerosis

The latest treatment for relapsing remitting multiple sclerosis is the long awaited tecfidera (dimethyl fumerate) also known as bg12.
This is an oral therapy twice a day with one week titration and little monitoring involved. Offers near 50% reduction in relapse rate.
Dr. William Gaya
Dr. William Gaya
Thank
Get help from a real doctor now
Dr. Adam Smith
Board Certified, Internal Medicine
13 years in practice
382K people helped
Continue
108,000 doctors available
Read more answers from doctors